Arrowhead Pharmaceuticals (ARWR)
(Delayed Data from NSDQ)
$23.29 USD
-0.49 (-2.06%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $22.84 -0.45 (-1.93%) 6:32 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
Arrowhead Pharmaceuticals, Inc. [ARWR]
Reports for Purchase
Showing records 1 - 20 ( 89 total )
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Hepatitis B Breakthrough Boom: Navigating a $450-$500 Billion Frontier
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 150.00
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
F1Q24 Results; Trims Pipeline to Focus on Liver and Lung Programs; Multiple Readouts on Track in 2024; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 25.00
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
IND Filing For Complement Mediated Kidney Disease Reinforces "20 in ''25" Strategic Goal; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 5.00
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY2023 Results; 20 in ''25 Strategy on Track; Pulmonary Platform Clears Safety Hurdle; Nears Multiple Readouts; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 25.00
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for ARWR 112123
Provider: Stock Traders Daily
Analyst: Research Department
Price: 12.50
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Unprecedented Results at AHA Place Cardio-Metabolic Pipeline on Track for Blockbuster Status
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 25.00
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
F3Q23 Results; Pipeline Progressing on Track; Nearing Key Pulmonary Preclinical Chronic Tox Data Readouts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Fazirsiran Appears on Track For Positive Outcome in Phase 3 REDWOOD Alpha One Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
RD Day Takeaways: 20 in ''25 Goal on Track; CNS, Pulmonary and Liver-Targeted Programs Progressing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 25.00
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
ARO-ANG3 Clears Initial Hurdle in Phase 2 Trial in Patients with HoFH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 5.00
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
F2Q23 Results; Expects to Unveil Plethora of Data at June 1 RD Day; Multiple Late Stage Programs Progessing on Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Phase 1/2 ARO-RAGE Program Clears First Hurdle; Next Update Expected at R&D Day on June 1; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 5.00
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
F1Q23 Earnings; Reports Broad Pipeline Progress; Attractively Valued Ahead of Myriad Pipeline Updates Expected in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Partnered Fazirsiran Advancing to Phase 3 in Alpha One; Plethora of Pipeline Updates on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Announces 20 in 2025 Strategy; Multiple Programs Advancing to Phase 3 in 2023; Moderating Price Target to $90
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 75.00
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
F3Q22 Earnings; Pipeline Is Firing on All Cylinders With Many Datasets on Track for 2H22 and 2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Partnered Program Updates; Alpha One Program Continues to Shine; HBV Data Confirms Potential Need for Immunomodulator
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 25.00
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Outlines Next Generation Pulmonary Programs With Blockbuster Potential in Asthma, COPD, and IPF
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 35.00
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Potential Blockbuster Partnered Olpasiran Program Addressing Cardiovascular Disease Clears Phase 2 Hurdle; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 5.00
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
F2Q22 Results; Pulmonary R&D Day Expected May 26; Alpha One Updates Expected Near-Term; CVD Programs on Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50